Lars Tönges

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/775777/publications.pdf

Version: 2024-02-01

		147801	6	4796
96	6,922	31		79
papers	citations	h-index		g-index
			_	
110	110	110		1.4070
112	112	112		14278
all docs	docs citations	times ranked		citing authors

#	Article	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
2	Mechanisms of acute axonal degeneration in the optic nerve in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6064-6069.	7.1	253
3	Axonal degeneration as a therapeutic target in the CNS. Cell and Tissue Research, 2012, 349, 289-311.	2.9	224
4	ROCK inhibition and CNTF interact on intrinsic signalling pathways and differentially regulate survival and regeneration in retinal ganglion cells. Brain, 2008, 131, 250-263.	7.6	215
5	ROCK2 is a major regulator of axonal degeneration, neuronal death and axonal regeneration in the CNS. Cell Death and Disease, 2014, 5, e1225-e1225.	6. 3	150
6	Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease. Brain, 2012, 135, 3355-3370.	7.6	142
7	ROCK inhibition in models of neurodegeneration and its potential for clinical translation. , 2018, 189, 1-21.		136
8	Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease. Acta Neuropathologica Communications, 2016, 4, 39.	5. 2	123
9	The spinal muscular atrophy disease protein SMN is linked to the rho-kinase pathway via profilin. Human Molecular Genetics, 2011, 20, 4865-4878.	2.9	120
10	Alpha-Synuclein affects neurite morphology, autophagy, vesicle transport and axonal degeneration in CNS neurons. Cell Death and Disease, 2015, 6, e1811-e1811.	6.3	102
11	Rho kinase inhibition modulates microglia activation and improves survival in a model of amyotrophic lateral sclerosis. Glia, 2014, 62, 217-232.	4.9	90
12	Stearylated octaarginine and artificial virus-like particles for transfection of siRNA into primary rat neurons. Rna, 2006, 12, 1431-1438.	3. 5	89
13	Tatâ€Hsp70 protects dopaminergic neurons in midbrain cultures and in the substantia nigra in models of Parkinson's disease. Journal of Neurochemistry, 2008, 105, 853-864.	3.9	85
14	TAT-Hsp70-Mediated Neuroprotection and Increased Survival of Neuronal Precursor Cells after Focal Cerebral Ischemia in Mice. Journal of Cerebral Blood Flow and Metabolism, 2009, 29, 1187-1196.	4.3	85
15	ROCKing regeneration: Rho kinase inhibition as molecular target for neurorestoration. Frontiers in Molecular Neuroscience, 2011, 4, 39.	2.9	83
16	Transduction of Neural Precursor Cells with TAT-Heat Shock Protein 70 Chaperone: Therapeutic Potential Against Ischemic Stroke after Intrastriatal and Systemic Transplantation. Stem Cells, 2012, 30, 1297-1310.	3.2	72
17	Association of Blood Pressure With Outcomes in Acute Stroke Thrombectomy. Hypertension, 2020, 75, 730-739.	2.7	72
18	GluN2D-containing NMDA receptors-mediate synaptic currents in hippocampal interneurons and pyramidal cells in juvenile mice. Frontiers in Cellular Neuroscience, 2015, 9, 95.	3.7	70

#	Article	IF	CITATIONS
19	BAG1 promotes axonal outgrowth and regeneration in vivo via Raf-1 and reduction of ROCK activity. Brain, 2008, 131, 2606-2619.	7.6	66
20	Classification of advanced stages of Parkinson's disease: translation into stratified treatments. Journal of Neural Transmission, 2017, 124, 1015-1027.	2.8	64
21	Hepatocyte growth factor protects retinal ganglion cells by increasing neuronal survival and axonal regeneration in vitro and in vivo. Journal of Neurochemistry, 2011, 117, 892-903.	3.9	58
22	Interventional Influence of the Intestinal Microbiome Through Dietary Intervention and Bowel Cleansing Might Improve Motor Symptoms in Parkinson's Disease. Cells, 2020, 9, 376.	4.1	57
23	Modulation of Microglial Activity by Rho-Kinase (ROCK) Inhibition as Therapeutic Strategy in Parkinson's Disease and Amyotrophic Lateral Sclerosis. Frontiers in Aging Neuroscience, 2017, 9, 94.	3.4	56
24	AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo. Neurobiology of Disease, 2015, 73, 150-162.	4.4	54
25	Emerging Immunotherapies for Parkinson Disease. Neurology and Therapy, 2019, 8, 29-44.	3.2	49
26	Deferiprone Rescues Behavioral Deficits Induced by Mild Iron Exposure in a Mouse Model of Alpha-Synuclein Aggregation. NeuroMolecular Medicine, 2017, 19, 309-321.	3.4	45
27	TGF- \hat{l}^2 1 enhances neurite outgrowth via regulation of proteasome function and EFABP. Neurobiology of Disease, 2010, 38, 395-404.	4.4	44
28	Rho Kinase Inhibition by Fasudil in the Striatal 6-Hydroxydopamine Lesion Mouse Model of Parkinson Disease. Journal of Neuropathology and Experimental Neurology, 2014, 73, 770-779.	1.7	42
29	Elemental fingerprint as a cerebrospinal fluid biomarker for the diagnosis of Parkinson's disease. Journal of Neurochemistry, 2018, 145, 342-351.	3.9	39
30	Clinical Profiles and Mortality of <scp>COVID</scp> â€19 Inpatients with Parkinson's Disease in Germany. Movement Disorders, 2021, 36, 1049-1057.	3.9	36
31	Altered Expression of Growth Associated Proteinâ€43 and Rho Kinase in Human Patients with Parkinson's Disease. Brain Pathology, 2017, 27, 13-25.	4.1	35
32	miR-182-5p and miR-183-5p Act as GDNF Mimics in Dopaminergic Midbrain Neurons. Molecular Therapy - Nucleic Acids, 2018, 11, 9-22.	5.1	34
33	Upregulation of reggie- 1 /flotillin- 2 promotes axon regeneration in the rat optic nerve in vivo and neurite growth in vitro. Neurobiology of Disease, 2013, 51, 168-176.	4.4	33
34	Rho Kinase Inhibition with Fasudil in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis—Symptomatic Treatment Potential after Disease Onset. Frontiers in Pharmacology, 2017, 8, 17.	3.5	32
35	Viral vector-mediated downregulation of RhoA increases survival and axonal regeneration of retinal ganglion cells. Frontiers in Cellular Neuroscience, 2014, 8, 273.	3.7	31
36	The Progressive Supranuclear Palsy Clinical Deficits Scale. Movement Disorders, 2020, 35, 650-661.	3.9	31

#	Article	IF	CITATIONS
37	Galectin-1 expression in human glioma cells: modulation by ionizing radiation and effects on tumor cell proliferation and migration. Oncology Reports, 2007, 18, 483-8.	2.6	31
38	Novel Immunotherapeutic Approaches to Target Alpha-Synuclein and Related Neuroinflammation in Parkinson's Disease. Cells, 2019, 8, 105.	4.1	30
39	Blood Contamination in CSF and Its Impact on Quantitative Analysis of Alpha-Synuclein. Cells, 2020, 9, 370.	4.1	30
40	Update on CSF Biomarkers in Parkinson's Disease. Biomolecules, 2022, 12, 329.	4.0	29
41	Impairment of Motor Function Correlates with Neurometabolite and Brain Iron Alterations in Parkinson's Disease. Cells, 2019, 8, 96.	4.1	28
42	JNK Isoforms Differentially Regulate Neurite Growth and Regeneration in Dopaminergic Neurons In Vitro. Journal of Molecular Neuroscience, 2011, 45, 284-293.	2.3	27
43	Calpain-mediated cleavage of collapsin response mediator protein-2 drives acute axonal degeneration. Scientific Reports, 2016, 6, 37050.	3.3	27
44	Combined inhibition of Cdk5 and ROCK additively increase cell survival, but not the regenerative response in regenerating retinal ganglion cells. Molecular and Cellular Neurosciences, 2009, 42, 427-437.	2.2	26
45	Dynamics of Parkinson's Disease Multimodal Complex Treatment in Germany from 2010–2016: Patient Characteristics, Access to Treatment, and Formation of Regional Centers. Cells, 2019, 8, 151.	4.1	26
46	Hematopoietic Cytokines - on the Verge of Conquering Neurology. Current Molecular Medicine, 2007, 7, 157-170.	1.3	25
47	Propionic Acid and Fasudil as Treatment against Rotenone Toxicity in an In Vitro Model of Parkinson's Disease. Molecules, 2020, 25, 2502.	3.8	25
48	Selenium speciation analysis in the cerebrospinal fluid of patients with Parkinson's disease. Journal of Trace Elements in Medicine and Biology, 2020, 57, 126412.	3.0	23
49	Elemental fingerprint: Reassessment of a cerebrospinal fluid biomarker for Parkinson's disease. Neurobiology of Disease, 2020, 134, 104677.	4.4	23
50	Parkinson's Disease Multimodal Complex Treatment improves motor symptoms, depression and quality of life. Journal of Neurology, 2020, 267, 954-965.	3.6	23
51	Blood-based biomarker in Parkinson's disease: potential for future applications in clinical research and practice. Journal of Neural Transmission, 2022, 129, 1201-1217.	2.8	23
52	Acute axonal degeneration in vivo is attenuated by inhibition of autophagy in a calcium-dependent manner. Autophagy, 2010, 6, 658-659.	9.1	22
53	Reversible Immuno-Infrared Sensor for the Detection of Alzheimer's Disease Related Biomarkers. ACS Sensors, 2019, 4, 1851-1856.	7.8	22
54	The rho kinase inhibitor Y-27632 improves motor performance in male SOD1G93A mice. Frontiers in Neuroscience, 2014, 8, 304.	2.8	21

#	Article	IF	CITATIONS
55	Alpha-synuclein mutations impair axonal regeneration in models of Parkinson's disease. Frontiers in Aging Neuroscience, 2014, 6, 239.	3.4	20
56	Specialized Staff for the Care of People with Parkinson's Disease in Germany: An Overview. Journal of Clinical Medicine, 2020, 9, 2581.	2.4	20
57	Imaging of rat optic nerve axons in vivo. Nature Protocols, 2011, 6, 1887-1896.	12.0	19
58	Motor, cognitive and mobility deficits in 1000 geriatric patients: protocol of a quantitative observational study before and after routine clinical geriatric treatment – the ComOn-study. BMC Geriatrics, 2020, 20, 45.	2.7	19
59	TDPâ€43 as structureâ€based biomarker in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2021, 8, 271-277.	3.7	17
60	Brainstem Raphe Alterations in TCS: A Biomarker for Depression and Apathy in Parkinson's Disease Patients. Frontiers in Neurology, 2018, 9, 645.	2.4	15
61	Lentiform Nucleus Hyperechogenicity in Parkinsonian Syndromes: A Systematic Review and Meta-Analysis with Consideration of Molecular Pathology. Cells, 2020, 9, 2.	4.1	15
62	Recommendations for Standards of Network Care for Patients with Parkinson's Disease in Germany. Journal of Clinical Medicine, 2020, 9, 1455.	2.4	15
63	Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis (ALS). Journal of Visualized Experiments, 2012, , .	0.3	14
64	Landscape of pain in Parkinson's disease: impact of gender differences. Neurological Research, 2019, 41, 87-97.	1.3	13
65	Structured Care and Self-Management Education for Persons with Parkinson's Disease: Why the First Does Not Go without the Second—Systematic Review, Experiences and Implementation Concepts from Sweden and Germany. Journal of Clinical Medicine, 2020, 9, 2787.	2.4	13
66	Analysis of nationwide multimodal complex treatment and drug pump therapy in Parkinson's disease in times of COVID-19 pandemic in Germany. Parkinsonism and Related Disorders, 2021, 85, 109-113.	2.2	12
67	Dyskinesia in multiple system atrophy and progressive supranuclear palsy. Journal of Neural Transmission, 2019, 126, 925-932.	2.8	11
68	Resource Utilization of Patients with Parkinson's Disease in the Late Stages of the Disease in Germany: Data from the CLaSP Study. Pharmacoeconomics, 2021, 39, 601-615.	3.3	11
69	A Propagated Skeleton Approach to High Throughput Screening of Neurite Outgrowth for In Vitro Parkinson's Disease Modelling. Cells, 2021, 10, 931.	4.1	10
70	Multiple sclerosis is not associated with an increased risk for severe COVID-19: a nationwide retrospective cross-sectional study from Germany. Neurological Research and Practice, 2021, 3, 42.	2.0	10
71	Coronal Transcranial Sonography and Mâ€Mode Tremor Frequency Determination in Parkinson's Disease and Essential Tremor. Journal of Neuroimaging, 2017, 27, 524-530.	2.0	9
72	Highâ€Resolution Nerve Ultrasound and Electrophysiological Findings in Restless Legs Syndrome. Journal of Neuroimaging, 2018, 28, 506-514.	2.0	9

#	Article	IF	CITATIONS
73	Short-chain fatty acids in the context of Parkinson's disease. Neural Regeneration Research, 2021, 16, 2015.	3.0	9
74	Fingolimod for Irradiation-Induced Neurodegeneration. Frontiers in Neuroscience, 2019, 13, 699.	2.8	8
75	Parkinson's Disease Multimodal Complex Treatment (PD-MCT): Analysis of Therapeutic Effects and Predictors for Improvement. Journal of Clinical Medicine, 2020, 9, 1874.	2.4	8
76	The impact of the COVID-19 pandemic on hospitalizations and plasmapheresis therapy in multiple sclerosis and neuromyelitis optica spectrum disorder: a nationwide analysis from Germany. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110306.	3.5	8
77	Immediate-release/extended-release amantadine (OS320) to treat Parkinson's disease with levodopa-induced dyskinesia: Analysis of the randomized, controlled ALLAY-LID studies. Parkinsonism and Related Disorders, 2022, 96, 65-73.	2.2	8
78	Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa–carbidopa intestinal gel, and deep brain stimulation. Journal of Neural Transmission, 2019, 126, 879-888.	2.8	7
79	SARS-CoV-2, COVID-19 and Parkinson's Diseaseâ€"Many Issues Need to Be Clarifiedâ€"A Critical Review. Brain Sciences, 2022, 12, 456.	2.3	7
80	Letter to the editor: risk comorbidities of COVID-19 in Parkinson's disease patients in Germany. Neurological Research and Practice, 2020, 2, 22.	2.0	6
81	Building a Parkinson-Network–Experiences from Germany. Journal of Clinical Medicine, 2020, 9, 2743.	2.4	6
82	Correlates of polyneuropathy in Parkinson's disease. Annals of Clinical and Translational Neurology, 2020, 7, 1898-1907.	3.7	5
83	Hospital Admissions for Neurodegenerative Diseases during the First Wave of the COVID-19 Pandemic: A Nationwide Cross-Sectional Study from Germany. Brain Sciences, 2021, 11, 1219.	2.3	4
84	Septic embolic encephalitis after Staphylococcus aureus endocarditis of a prosthetic valve in a 57-year-old woman: a case report. Cases Journal, 2009, 2, 6653.	0.4	3
85	Emergence of Bruxism after Reducing Left Pallidal Stimulation in a Patient with Huntington's Disease. Movement Disorders Clinical Practice, 2020, 7, 704-705.	1.5	3
86	Hospitalization Rates and Comorbidities in Patients with Progressive Supranuclear Palsy in Germany from 2010 to 2017. Journal of Clinical Medicine, 2020, 9, 2454.	2.4	3
87	Antibody-based immunotherapies for Parkinsonian syndromes. Neural Regeneration Research, 2019, 14, 1903.	3.0	3
88	CSF Sample Preparation for Data-Independent Acquisition. Methods in Molecular Biology, 2019, 2044, 61-67.	0.9	2
89	Disease modifying treatment trials in Parkinson's disease: how to balance expectations and interests of patients, physicians and industry partners?. Neurological Research and Practice, 2020, 2, 31.	2.0	2
90	Brainstem Encephalitis With Low-Titer Acetylcholine Receptor Antibodies Mimicking Myasthenia Gravis. Frontiers in Neurology, 2019, 10, 829.	2.4	1

Lars Tönges

#	Article	IF	CITATION
91	Comment on: A 57â€Yearâ€Old Woman With Progressive Left Hand Clumsiness and Falls. Movement Disorders Clinical Practice, 2020, 7, 579-580.	1.5	1
92	Prevalence and Characteristics of Polyneuropathy in Atypical Parkinsonian Syndromes: An Explorative Study. Brain Sciences, 2021, 11, 879.	2.3	1
93	Monogenetic Forms of Parkinson's Disease – Bridging the Gap Between Genetics and Biomarkers. Frontiers in Aging Neuroscience, 2022, 14, 822949.	3.4	1
94	COVID-19 outcomes in hospitalized Parkinson's disease patients in two pandemic waves in 2020: a nationwide cross-sectional study from Germany. Neurological Research and Practice, 2022, 4, .	2.0	1
95	SARS-CoV-2, COVID-19 and Neurodegeneration. Brain Sciences, 2022, 12, 897.	2.3	1
96	Residents as teachers in Neurology: a Germany-wide survey on the involvement of neurological residents in clinical teaching. Neurological Research and Practice, 2022, 4, 17.	2.0	0